Literature DB >> 23328771

Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.

Alain M Schoepfer1, Christoph Beglinger, Alex Straumann, Ekaterina Safroneeva, Yvonne Romero, David Armstrong, Carsten Schmidt, Michael Trummler, Valérie Pittet, Stephan R Vavricka.   

Abstract

BACKGROUND: The correlation between noninvasive markers with endoscopic activity according to the modified Baron Index in patients with ulcerative colitis (UC) is unknown. We aimed to evaluate the correlation between endoscopic activity and fecal calprotectin (FC), C-reactive protein (CRP), hemoglobin, platelets, blood leukocytes, and the Lichtiger Index (clinical score).
METHODS: UC patients undergoing complete colonoscopy were prospectively enrolled and scored clinically and endoscopically. Samples from feces and blood were analyzed in UC patients and controls.
RESULTS: We enrolled 228 UC patients and 52 healthy controls. Endoscopic disease activity correlated best with FC (Spearman's rank correlation coefficient r = 0.821), followed by the Lichtiger Index (r = 0.682), CRP (r = 0.556), platelets (r = 0.488), blood leukocytes (r = 0.401), and hemoglobin (r = -0.388). FC was the only marker that could discriminate between different grades of endoscopic activity (grade 0, 16 [10-30] μg/g; grade 1, 35 [25-48] μg/g; grade 2, 102 [44-159] μg/g; grade 3, 235 [176-319] μg/g; grade 4, 611 [406-868] μg/g; P < 0.001 for discriminating the different grades). FC with a cutoff of 57 μg/g had a sensitivity of 91% and a specificity of 90% to detect endoscopically active disease (modified Baron Index ≥ 2).
CONCLUSIONS: FC correlated better with endoscopic disease activity than clinical activity, CRP, platelets, hemoglobin, and blood leukocytes. The strong correlation with endoscopic disease activity suggests that FC represents a useful biomarker for noninvasive monitoring of disease activity in UC patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328771     DOI: 10.1097/MIB.0b013e3182810066

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  82 in total

1.  Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population.

Authors:  Oriano Radillo; Lorella Pascolo; Stefano Martelossi; Sara Dal Bo; Alessandro Ventura
Journal:  J Clin Lab Anal       Date:  2016-02-15       Impact factor: 2.352

2.  Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Shiho Takashima; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

3.  Monocytosis and a Low Lymphocyte to Monocyte Ratio Are Effective Biomarkers of Ulcerative Colitis Disease Activity.

Authors:  Cynthia E Cherfane; Luke Gessel; Dominic Cirillo; Miriam B Zimmerman; Steven Polyak
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325

Review 4.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

5.  Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.

Authors:  Antonio Tursi; Walter Elisei; Marcello Picchio; GianMarco Giorgetti; Giovanni Brandimarte
Journal:  Dig Dis Sci       Date:  2014-12-02       Impact factor: 3.199

6.  Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.

Authors:  Emanuel Burri; Christoph Beglinger; Stefanie von Felten; Frank Serge Lehmann
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

Review 7.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

8.  Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases.

Authors:  Mehdi Torki; Ali Gholamrezaei; Leila Mirbagher; Manijeh Danesh; Sara Kheiri; Mohammad Hassan Emami
Journal:  Dig Dis Sci       Date:  2015-06-02       Impact factor: 3.199

9.  How useful are blood and stool biomarkers for detecting subclinical mucosal inflammation in ulcerative colitis?

Authors:  Byong Duk Ye
Journal:  Dig Dis Sci       Date:  2014-01-17       Impact factor: 3.199

Review 10.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.